Copy shortlink:
In less than two months, the U.S. Food and Drug Administration is supposed to decide, at long last, whether the company most responsible for the teenage vaping epidemic should be stopped, or at least restrained, from marketing its e-cigarettes.
The decision will hinge on whether scientific research shows that Juul's sleek nicotine-delivery device has public health benefits. Does it enable smokers to break or reduce their addiction to cigarettes? Or does it primarily lead to dual use of e-cigs and traditional cigarettes, while luring nonsmokers - especially young people - into nicotine addiction?
Juul, which is partly owned by tobacco giant Altria, decided to add to that scientific evidence.